Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ

Current Topics in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 738-753

  Ameriks, Michael K ^a   Venable, Jennifer D ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Allergy; Asthma; COPD; Inflammation; PI3K; Rheumatoid arthritis

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 AMINOHETEROCYCLE INHIBITOR; 2 AMINOTHIAZOLE INHIBITOR; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; AMIDOTETRAZOLE; CAL 101; CAL 263; IMIDAZOLOPYRIDAZINE INHIBITOR; MORPHOLINOTHIAZOLE INHIBITOR; NATURAL PRODUCT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE DELTA; PHOSPHOINOSITIDE 3 KINASE DELTA INHIBITOR; PHOSPHOINOSITIDE 3 KINASE GAMMA; PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITOR; PIK 39; PROTEIN P110; PROTEIN P110 DELTA; PROTEIN P110 GAMMA; PTERIDINE INHIBITOR; PYRIMIDINYLMORPHOLINE INHIBITOR; QUINAZOLINONE DERIVATIVE; QUINOXALINE; STAUROSPORINE; TARGEGEN; TG 100 115; THIAZOLIDINONE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG; WO 08000421;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME CONFORMATION; GENE DELETION; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; NONHUMAN; PAW EDEMA; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BIOLOGICAL PRODUCTS; DRUG DESIGN; HUMANS; ISOENZYMES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SMALL MOLECULE LIBRARIES;

EID: 70350132390     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789044434     Document Type: Review

References (139)

1. Vanhaesebroeck, B.; Leevers, S. J.; Khatereh, A.; Timms, J.; Katso, R.; Driscoll, P. C.; Woscholski, R.; Parker, P. J.; Waterfield, M. D. Synthesis and function of 3-phosphorylated inositol lipids. Ann. Rev. Biochem. 2001, 70, 535-602.
2. Jimenez, C.; Hernandez, C.; Pimentel, B.; Carrera, A. C. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J. Biol. Chem. 2002, 277, 41556-41562.
3. Brock, C.; Schaefer, M.; Reusch, H. P.; Czupalla, C.; Michalke, M.; Spicher, K.; Schultz, G.; Nurnberg, B. Roles of G βγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ. J. Cell Biol. 2003, 160, 89-99
4. Bi, L.; Okabe, I.; Bernard, D. J.; Wynshaw-Boris, A.; Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 1999, 274, 10963-10968.
5. Bi, L.; Okabe, I.; Bernard, D. J.; Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI3-kinase. Mamm. Genome 2002, 13, 169-172.
6. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Sci. 2008, 99, 1734-1740.
7. Maira, S.-M.; Voliva, C.; Garcia-Echeverria, C. Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Expert Opin. Ther. Targets 2008, 12, 223-238.
8. Verheijen, J. C.; Zask, A. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs. Drugs Future 2007, 32, 537-547.
9. Rommel, C.; Camps, M.; Ji, H. PI3K and PI3Kγ: Partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007, 7, 191-201.
10. Ruckle, T.; Schwarz, M. K.; Rommel, C. PI3Kγ inhibition: Towards an 'aspirin of the 21st century'? Nat. Rev. Drug Disc. 2006, 5, 903-918.
11. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase- moving towards therapy. Biochim. Biophys. Acta 2008, 1784, 159-185.
12. Ghigo, A.; Hirsch, E. Isoform selective phosphoinositide 3-kinase γ and δ inhibitors and their therapeutic potential. Rec. Patents Inflamm. Allergy Drug Disc. 2008, 2, 1-10.
13. Barberis, L.; Hirsch, E. Targeting phosphoinositide 3-kinase γ to fight inflammation and more. Thromb. Haemost. 2008, 99, 279-285.
14. Puri, K. D. Therapeutic potential of phosphoinositide 3-kinase δ-selective small molecule inhibitors. Curr. Enzyme Inhib. 2006, 2, 147-161.
15. Ito, K.; Caramori, G.; Adcock, I. M. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharm. Exp. Ther. 2007, 321, 1-8.
16. Sundstrom. T. J.; Anderson, A. C.; Wright, D. L. Inhibitors of phosphoinositide-3-kinase: A structure-based approach to understanding potency and selectivity. Org. Biomol. Chem. 2009, 7, 840-850.
17. Huang, C. H. The structure of a human p110/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 2007, 318, 1744-1748.
18. Walker, E. H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural insights into phosphoinositide 3-kinase signalling. Nature 1999, 402, 313-320.
19. Xie, P.; Williams, DS.; Atilla-Gokcumen, G. E.; Milk, L.; Xiao, M.; Smalley, K. S. M.; Herlyn, M.; Meggers, E.; Marmorstein, R. Structure-based design of an organoruthenium phosphatidylinositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 2008, 3, 305-316.
20. Pomel, V.; Klicic, J.; Covini, D.; Church, D. D.; Shaw, J. P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P.-A.; Carboni, S.; Rommel, C.; Schwarz, M. K.; Ruckle, T. Furan-2-ylmethylene thiazoli-dine-diones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem. 2006, 49, 3857-3871.
21. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P.-A.; Hirsch, E.; Wymann, M. P.; Cirillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005, 11, 936-943.
22. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6, 909-919.
23. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted pharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem Biol. 2008, 4, 691-699.
24. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006, 125, 733-747.
25. Zvelebil, M. J.; Waterfield, M. D.; Shuttleworth, S. J. Arch. Biochem. Biophys. 2008, 477, 404-410.
26. Frazzetto, M.; Suphioglu, C.; Zhu, J.; Schmidt-Kittler, O.; Jennings, I. G.; Cranmer, S. L.; Jackson, S. P.; Kinzler, K. W.; Vogelstein, B.; Thompson, P. E. Dissecting isoform selectivity of PI3K inhibitors: The role of non-conserved residues in the catalytic pocket. Biochem J. 2008, 414, 383-390.
27. Liao, J. J-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 2007, 50, 409-424.
28. Blencke, S.; Zech, B.; Engkvist, O.; Greff, Z.; Orfi, L.; Horvath, Z.; Keri, G.; Ullrich, A.; Daub, H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 2004, 11, 691-701.
29. Alaimo, P. J.; Knight, Z. A.; Shokat, K. M. Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg. Med. Chem. 2005, 13, 2825-2836.
30. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
31. Wipf, P.; Halter, R. J. Chemistry and biology of wortmannin. Org. Biomol. Chem. 2005, 3, 2053-2061.
32. Arcaro, A.; Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 1993, 296, 297-301.
33. Yano, H.; Nakanishi, S.; Kimura, K.; Hanai, N.; Saitoh, Y.; Fukui, Y.; Nonomura, Y.; Matsuda, Y. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinsoitol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 1993, 268, 25846-25856.
34. Wymann, M. P.; Bulgarelli-Leva, G.; Zvelebil, M. J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M. D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell Biol. 1996, 16, 1722-1733.
35. Ihle, N. T.; Paine-Murrieta, G.; Berggren, M. I.; Baker, A.; Tate, W. R.; Wipf, P.; Abraham, R. T.; Kirkpatrick, D. L.; Powis, G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 2005, 4, 1349-1357.
36. Nakanishi, S.; Catt, K. J.; Balla, T. A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids. Proc. Natl. Acad. Sci. USA 1995, 92, 5317-5321.
37. Sarkaria, J. N.; Tibbetts, R. S.; Busby, E. C.; Kennedy, A. P.; Hill, D. E.; Abraham, R. T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998, 58, 4375-4382.
38. Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. A.; Johnson, D. W.; Rutherford, P. G.; Schultz, R. M.; Worzalla, J. F.; Vlahos, C. J. Studies on the mechanism of phospatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem. 1996, 39, 1106-1111.
39. Norman, B. H.; Paschal, J.; Vlahos, C. J. Synthetic studies on the furan ring of wortmannin. Biorg. Med. Chem. Lett. 1995, 5, 1183-1186.
40. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 3, 763-772.
41. Clinical trials database homepage. http://clinicaltrials.gov Identifier: NCT00726583, (6/18/09).
42. Matter, W. F.; Brown, R. F.; Vlahos, C. J. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem. Biophys. Res. Commun. 1992, 186, 624-631.
43. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyranon-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
44. Gharbi, S. I.; Zvelebil, M. J.; Shuttleworth, S. J.; Hancox, T.; Saghir, N.; Timms, J. F.; Waterfield, M. D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 2007, 404, 15-21.
45. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132
46. Foukas, L. C.; Daniele, N.; Ktori, C.; Anderson, K. E.; Jensen, J.; Shepherd, P. R. Direct effects of caffeine and theophylline on p110 and other phosphoinositide 3-kinases. J. Biol. Chem. 2002, 277, 37124-37130.
47. Sadhu, C.; Dick, K.; Treiberg, J.; Sowell, C. G.; Kesicki, E. A.; Oliver, A. Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta. WO01081346, 2001.
48. Sadhu, C.; Dick, K.; Treiberg, J.; Sowell, C. G.; Kesicki, E. A.; Oliver, A. Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta. US02161014 2002.
49. Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C.G.; Staunton, D. E. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol. 2003, 170, 2647-2654.
50. Puri, K. D.; Doggett, T. A.; Douangpanya, J.; Hou, Y.; Tino, W. T.; Wilson, T.; Graf, T.; Clayton, E.; Turner, M.; Hayflick, J. S.; Diacovo, T. G. Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Immunobiol. 2004, 103, 3448-3456.
51. Sadhu, C.; Dick, K.; Tino, W. T.; Staunton, D. E. Selective role of PI3Kδ in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 2003, 308, 764-769.
52. Randis, T. M.; Puri, K. D.; Zhou, H.; Diacovo, T. G. Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils. Eur. J. Immunol. 2008, 38, 1215.
53. Wedemeyer, J.; Galli, S. J. Mast cells and basophils in acquired immunity. Br. Med. Bull. 2000, 56, 936-955.
54. Ali, K.; Bilancio, A.; Thomas, M.; Pearce, W.; Gilfillan, A. M.; Tkacyk, C.; Kuehn, N.; Gray, A.; Giddings, J.; Peskett, E.; Fox, R.; Bruce, I.; Walker, C.; Sawyer, C.; Okkenburg, K.; Finan, P.; Vanhaesebroeck, B. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004, 431, 1007-1011
55. Ali, K.; Camps, M.; Pearce, W. P.; Ji, H.; Ruckle, T.; Kuehn, N.; Pasquali, C.; Chabert, C.; Rommel, C.; Vanhasebroeck, B. Isoformspecific functions of phosphoinositide 3-kinases: P110δ but not p110γ promotes optimal allergic responses in vivo. J. Immunol. 2008, 180, 2538-2544.
56. Laffargue, M.; Calvez, R.; Finan, P.; Trifilieff, A.; Barbier, M..; Altruda, F.; Hirsch, E.; Wymann, M. P. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 2002, 16, 441-451.
57. Lee, K. S.; Park, S. J.; Kim, S. R.; Min, K. H.; Jin, S. M.; Puri, K. D.; Lee, Y. C. Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma. J. Allergy Clin. Immunol. 2006, 118, 403-409.
58. Lee, K. S.; Lee, H. K.; Hayflick, J. S.; Lee, Y. C.; Puri, K. D. Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 2006, 20, 455-465.
59. Park, S. J.; Min, K. H.; Lee, Y. C. Phosphoinositide 3-kinase δ inhibitor as a novel therapeutic agent in asthma. Respirology 2008, 13, 764-771.
60. Sujobert, P.; Bardet, V.; Cornillet-Lefebvre, P.; Hayflick, J. S.; Prie, N.; Verdier, F.; Vanhaesebroeck, B.; Muller, O.; Pesce, F.; Ifrah, N.; Hunault-Berger, M.; Berthou, C.; Villemagne, B.; Jourdan, E.; Audhuy, B.; Solary, E.; Witz, B.; Harousseau, J. L.; Himberlin, C.; Lamy, T.; Lioure, B.; Cahn, J. Y.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106, 1063-1066.
61. Calistoga Pharmaceuticals press release, March 5, 2007; www.calistogapharma.com
62. Calistoga Pharmaceuticals press release, June 9, 2009; www.calistogapharma.com
63. Clinical trials database homepage. http://clinicaltrials.gov Identifier: NCT00836914, (6/18/09).
64. Amzel, L. M.; Huang, C.-H.; Mandelker, D.; Lengauer, C.; Gabelli, S. B.; Vogelstein, B. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer 2008, 8, 665-669.
65. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem Biol. 2006, 2, 358-364.
66. Knight, Z. A.; Shokat, K. M. Chemically targeting the PI3K family. Biochem. Soc. Trans. 2007, 35, 245-249.
67. Knight, Z.; Shokat, K. M.; Williams, O. PI3 kinase antagonists. WO2008127226, 2008.
68. Knight, Z.; Shokat, K. M.; Williams, O. PI3 kinase antagonists. US20080032960, 2008.
69. Knight, Z.; Apsel, B.; Shokat, K. M. Kinase antagonists. US20070293516, 2007.
70. White, S. L.; Ruan, F.; Kesicki, E. A.; Thorsett, E.; Farouz, F. Inhibitors of phophatidyl-inositol-3-kinase delta. WO064802, 2009.
71. White, S. L. Thienopyrimidinones for treatment of inflammatory disorders and cancers. WO2008064018, 2008.
72. Annelated azaheterocycles comprising pyrimidine fragment, method for the production thereof and (PI3Ks) kinase inhibitors. WO2009011617, 2009.
73. Chen, Y.; Cushing, T. D.; Hao, X.; He, X.; Reichelt, A.; Rzasa, R. M.; Seganish, J.; Shin, Y.; Zhang, D. ??3-Substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol-3-kinase (PI3K) inhibitors. WO2008118455, 2008.
74. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.-I.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4- morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg. Med. Chem. Lett. 2006, 14, 6847-6858.
75. Chuckowree, I.; Folkes, A.; Hancox, T.; Shuttleworth, S. Pharmaceutical compounds. WO07129161, 2007.
76. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl- Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salpathu, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-ylthieno 3,2,-dpyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51, 5522-5532.
77. Clinical trials database homepage. http://clinicaltrials.gov Indentifier: NCT00876109, (6/18/09).
78. Clinical trials database homepage. http://clinicaltrials.gov Indentifier: NCT00876122, (6/18/09).
79. Hancox, T. C.; Pegg, N. A.; Nadin, A. J.; Price, S. Thienopyrimidine derivatives as PI3K inhibitors. WO053715, 2009.
80. Goldsmith, P.; Hancox, T. C.; Hudson, A.; Pegg, N. A.; Kulagowski, J. J.; Nadin, A. J.; Price, S. Purine derivatives useful as PI3 kinase inhibitors. WO2009053716, 2009.
81. Baker, S. J.; Goldsmith, P. J.; Hancox, T. C.; Pegg, N. A.; Shuttleworth, S. J.; Dechaux, E. A.; Krintel, S. L.; Price, S.; Large, J. M.; MacDonald, E. Pharmaceutical compounds. WO2008125833, 2008.
82. Goldsmith, P. J.; Hancox, T. C.; Pegg, N. A.; Shuttleworth, S. J.; Large, J. M.; MacDonald, E. 2-Morpholin-4-yl-pyrimidines as PI3K inhibitors. WO2008125835, 2008.
83. Goldsmith, P. J.; Hancox, T. C.; Pegg, N. A.; Shuttleworth, S. J.; Large, J. M.; Dechaux, E. A.; Price, S.; MacDonald, E. Pharmaceutical compounds. WO2008125839, 2008.
84. Baker, S. J.; Hancox, T. C.; Pegg, N. A.; Nadin, A. J.; Price, S. Quinazoline derivatives as PI3K inhibitors. WO2008152387, 2008.
85. Hancox, T. C.; Pegg, N. A.; Beswick, M. C.; Blench, T. J.; Dechaux, E. A.; Kulagowski, J. J.; Nadin, A. J.; Price, S. Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase. WO2008152390, 2008.
86. Alexander, R.; Balasundaram, A.; Batchelor, M.; Brookings, D.; Crabbe, T.; Deltent, M.-F.; Driessens, F.; Gill, A.; Harris, S.; Hutchinson, G.; Kitahara, K.; Kulisa, C.; Merriman, M.; Mistry, P.; Parton, T.; Turner, J.; Whitcombe, I.; Wright, S. 4-(1,3-Thiazol-2- yl)morpholine derivatives as inhibitors of phosphoinositide 3- kinase. Bioorg. Med. Chem. Lett. 2008, 18, 4316-4320.
87. Alexander, R. P.; Aujla, P.; Batchelor, M. J.; Brookings, D. C.; Buckley, G. M.; Crepy, K. V. L.; Kulisa, C. L.; Turner, J. P. WO2006114606, 2006.
88. Perry B.; Alexander R; Bennett G.; Buckley, G.; Ceska, T.; Crabbe, T.; Dale, V.; Gowers, L.; Horsley, H.; James, L.; Jenkins, K.; Kitahara, K.; Kulisa, C.; Lightfoot, H.; Lock, C.; Mack, S.; Morgan, T.; Nicolas, A.-L.; Pitt, W.; Sabin, V.; Wright, S. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines. Bioorg. Med. Chem. Lett., 2008, 18, 4700-4704.
89. Alexander, R. P.; Aujla, P. S.; Crepy, K. V. L.; Foley, A. M.; Franklin, R. J.; Haughan, A. F.; Horsley, H. T.; Jones, W. M.; Lallemand, B. I. L.; Mack, S. R.; Morgan, T.; Pasau, P. M. G.; Phillips, D. J.; Sabin, V. M.; Buckley, G. M.; Jenkins, K.; Perry, B. G. Fused thiazole derivatives as PI3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008001076, 2008.
90. Perry B.; Beevers R.; Bennett G.; Buckley, G.; Crabbe, T.; Gowers, L.; James, L.; Jenkins, K.; Lock, C.; Sabin, V.; Wright, S. Optimization of a series of multi-isoform PI3 kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 5299-5302.
91. Alexander, R. P.; Bailey, S.; Brand, S.; Brookings, D. C.; Brown, J. A.; Haughan, A. F.; Kinsella, N.; Lowe, C.; Mack, S. R.; Pitt, W. R.; Richard, M. D.; Sharpe, A.; Tait, L. J. Fused thiophene derivatives as kinase inhibitors. WO2007141504, 2007.
92. Buckley, G. M.; Morgan, T.; Sabin, V. M. Fused thiazole derivatives as kinase inhibitors. WO2008044022, 2008.
93. Alexander, R. P.; Brown, J. A.; Crepy, K. V. L.; Mack, S. R. Thiazole derivatives as kinase inhibitors. WO2008047109, 2008.
94. Palanki, M. S. S.; Dneprovskaia, E.; Doukas, J.; Fine, R. M.; Hood, J.; Kang, X.; Lohse, D.; Martin, M.; Noronha, G.; Soll, R. M.; Wrasidlo, W.; Yee, S.; Zhu, H. Discovery of 3,3′-(2,4-diaminopteridine- 6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J. Med. Chem. 2007, 50, 4279.
95. Doukas, J.; Wrasidlo, W.; Noronha, G.; Dneprovskaia, E.; Fine, R.; Weis, S.; Hood, J.; DeMaria, A.; Soll, R.; Cheresh, D. Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Nat. Acad. Sci. 2006, 103, 19866-19871.
96. Doukas, J.; Wrasidlo, W.; Noronha, G.; Dneprovskaia, E.; Hood, J.; Soll, R. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem. Soc. Trans. 2007, 35, 204-206.
97. Clinical trials database homepage. http://clinicaltrials.gov Identifier: NCT00103350, (6/18/09).
98. Doukas, J.; Eide, L.; Stebbins, K.; Racanelli-Layton, A.; Dellamary, L.; Martin, M.; Dneprovskaia, E.; Noronha, G.; Soll, R.; Wrasidlo, W.; Acevedo, L. M.; Cheresh, D. A. Aerosolized phosphoinositide 3-kinase γ/δ inhibitor TG100-115 [3-]2,4- diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2009, 328, 758-765.
99. Rueckle, T.; Jiang, X.; Gaillard, P.; Church, D.; Vallotton, T. Azolidinone-vinyl fused-benzene derivatives. WO2004007491, 2004.
100. Rueckle, T., Shaw, J., Church, D., Covini, D. 2-Imino-4-(thio)oxo- 5-polycyclovinylazolines for use as PI3 kinase inhibitors. WO011686, 2005.
101. Rueckle, T.; Quattropani, A.; Pomel, V.; Dorbais, J.; Covini, D.; Bischoff, A. Pyridine methylene azolidinones and use there of phosphoinositide inhibitors. WO20024666, 2006.
102. Yki-Jarvinen, H. Thiazolidinediones. New Engl. J. Med. 2004, 351, 1106-1118.
103. Fougerat, A.; Gayral, S.; Gourdy, P.; Schambourg, A.; Ruckle, T.; Schwarz, M. K.; Rommel, C.; Irsch, E.; Arnal, J.-F.; Salles, J.-P.; Perret, B.; Breton-Douillon, M.; Wymann, M. P.; Laffargue, M. Genetic and pharmacological targeting of phosphoinositide 3- kinase-γ reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008, 117, 1310-1317.
104. Barber, D. F.; Bartolome, A.; Hernandez, C.; Flores, J. M.; Redondo, C.; Fernandez-Arias, C.; Camps, M.; Ruckle, T.; Schwarz, M. K.; Rodriguez, S.; Martinez, A-C.; Balomenos, D.; Rommel, C.; Carrera, A. C. PI3Kg inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 2005, 11, 933-935.
105. Noronha, G.; Mak, C. C.; Palanki, M. Thiazolidine compounds, and methods of making and using same. WO20026346, 2009.
106. Barvian, N. C.; Kolz, C. N.; Para, K. S.; Patt, W. C.; Visnick, M. Benzoxazine-3-ones and derivatives thereof as inhibitors of PI3K. WO2004052373, 2004.
107. Gogliotti, R. D.; Muccioli, K. L.; Para, K. S.; Visnick, M. Benzoxazines and derivatives thereof as inhibitors of PI3Ks. WO2004056820, 2004.
108. Lanni, T. B. Jr.; Greene K. L.; Kolz, C. N.; Para, K. S.; Visnick, M.; Mobley, J. L.; Dudley, D. T.; Baginski, T. J.; Liimatta, M. B. Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinaseγ. Bioorg. Med. Chem. Lett. 2007, 17, 756-760.
109. Bruce, I.; Finan, P.; Leblanc, C.; McCarthy, C.; Whitehead, L.; Blair, N. E.; Bloomfield, G. C.; Hayler, J.; Kirman, L.; Oza, M. S.; Shukla, L. 5-Phenylthiazole derivatives and their use as PI3 kinase inhibitors. WO20072557, 2003.
110. Bloomfield, G. C.; Bruce, I.; Hayler, J. F.; LeBlanc, C.; Legrand, D. M.; McCarthy, C. Organic compounds. WO05021519, 2005.
111. Bloomfield, G. C.; Bruce, I.; Leblanc, C.; Oza, Mrinalini S.; Whithead, L.; Cuenoud, B.; Keller, T. H.; Kirman, L.; McCarthy, C.; Woodward, G. E. 5-Phenylthiazole derivatives and use as PI3 kinase inhibitors US20060148822, 2006.
112. Budd, E.; Fox, H. J.; Ian B.; Legrand, D. M.; Cox, B.; Roth, P. R. 5-Phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors. WO2007134827, 2007.
113. Bruce, I.; Cuenoud, B.; Keller, T. H.; Pilgrim, G. E.; Press, N.; Le Grand, D. M.; Ritchie, C.; Valade, B.; Hayler, J.; Budd, E. Inhibitors of phosphatidylinositol 3-kinase. US20070032487, 2007.
114. Budd, E.; Hatto, J. D. I.; Hayler, J. F.; Legrand, D. M.; Valade, B. Organic compounds. WO2007068473, 2007.
115. Bruce, I.; Weitz, S. G. Organic compounds. WO2008000421, 2008.
116. Bruce, I.; Dunstan, A.; Hunt, T. A.; Howsham, C. Organic compounds. WO2009013348, 2009.
117. Brandl, T.; Maier U.; Hoffmann, M.; Scheuerer, S.; Joergensen, A. T.; Pautsch, A.; Breitfelder, S.; Grauert, M.; Hoenke, C.; Erb, K.; Pieper, M.; Pragst I. Thiazolyl-dihydroquinazolines. WO2007115929, 2007.
118. Maier, U.; Grauert, M.; Hoffmann, M.; Hoenke, C.; Joergensen, A. T.; Pautsch, A.; Brandl, T.; Breitfelder, S.; Scheuerer, S.; Erb, K.; Pieper, M.; Pragst, I. Thiazolyldihydroindazoles. WO2007115930, 2007.
119. Breitfelder, S.; Maier, U.; Hoenke, C.; Joergensen, A. T.; Pautsch, A.; Brandl, T.; Grauert, M.; Hoffmann, M.; Scheuerer, S.; Erb, K.; Pieper, M.; Pragst I. Thiazolyl-dihydrocyclopentapyrazoles for use as PI3-kinase inhibitors. WO2007115931, 2007.
120. Grauert, M.; Maier, U.; Hoffman, M.; Scheuerer, S.; Joergensen, A. T.; Pautsch, A.; Brandl, T.; Hoenke, C.; Breitfelder, S.; Klaus, E.; Pieper, M.; Pragst, I. Thiazolyl-dihydro-indazole. US20090093474, 2009.
121. Wang, T.; Green, J.; Cornebise, M.; Ledford, B.; Parsons, J.; Tanner, A.; Westcott, J. Inhibitors of phosphatidylinositol 3-kinase. WO2008027584, 2008.
122. Moffat, D. C. F.; Davies, S.; Alesso, S. M.; Launay, D. F. M.: WO2007129048, 2007.
123. Quattropani, A.; Rueckle,T.; Schwarz, M.; Dorbais, J.; Sauer, W.; Cleva, C.; Desforges, G. Thiazole derivatives and use thereof. WO2005068444, 2005.
124. Quattropani, A.; Pomel, V.; Rueckle, T.; Grippi-Vallotton, T. Thiazole derivatives and use thereof. WO2007082956, 2007.
125. Giovannini, R.; Frattini, S.; Brandl, T.; Breitfelder, S.; Cereda, E.; Grauer, M.; Hoffmann, M.; Joergensen, A. T.; Maier U.; Pautsch A.; Quai, M.; Scheuerer, S. Pteridinone derivatives as PI3-kinases inhibitors. WO2008092831, 2008.
126. Bruendl, M. M.; Gogliotti, R. D.; Goodman, A. P.; Reichard, G. A. Pyrrolyl-substituted pyrido[2,3-D]pyrimidin-7-ones and derivatives thereof as therapeutic agents. US20080255162, 2008.
127. Shimada, M.; Murata, T.; Fuchikami, K.; Tsujishita, H.; Omori, N.; Kato, I.; Miura, M.; Urbahns, K.; Gantner, F.; Bacon, K. Fused azole-pyrimidine derivatives. WO2004029055, 2004.
128. Bruce, I.; Hayler, J. F.; Bloomfield, G. C.; Edwards, L.; Cox, B.; Howsham, C. Pyrazolo3,4-Dpyrimidine derivatives useful to treat respiratory disorders. WO2007134828, 2007.
129. Gaillard, P.; Quattropani A.; Pomel, V.; Rueckle, T.; Klicic, J.; Church, D. Pyrazine derivatives and use as PI3K inhibitors. WO2007023186, 2007.
130. Connolly, M. K.; Gogliotti, R. D.; Plummer, M. S.; Visnick, M. Pyrimidines as inhibitors of phosphoinositide 3-kinases (PI3K). WO2005042519, 2005.
131. Robertson, D. G.; Datta, K.; Wells, D.; Egnash, L.; Robosky, L.; Manning, M.; Rohde, C.; Reily, M. D. Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase. Chem. Res. Toxicol. 2007, 20, 1871-1877.
132. Gogliotti, R. D.; Lee, H. T.; Sexton, K. E.; Visnick, M. Tetrazol benzofurancarboxamides with PI3K activity as therapeutic agents. WO2004108709, 2004.
133. Bruendl, M. M.; Connolly, M. K.;Goodman, A. P.; Gogliotti, R. D.; Lee, H. T.; Plummer, M. S.; Sexton, K. E.; Reichard, G. A.; Visnick, M.; Wilson, M. W.; Shahripour, A. B. 3-Aryloxy and 3- heteroaryloxy substituted benzo(B) thiophenes as therapeutic agents with PI3K activity. WO2004108715, 2004.
134. Connolly, M. K.; Cogliotti, R. D.; Hurt, C. R.; Reichard, G. A.; Visnick, M. Halo substituted benzo(B) thiophenes with PI3K inhibitory activity as therapeutic agents. WO2005023800, 2005.
135. Wilson, F.; Ramsden, N.; Bell, K.; Cansfield, A.; Burckhardt, S.; Taylor, J.; Sunose, M.; Middlemiss, D. Triazole derivatives as kinase inhibitors. WO2008025821, 2008.
136. Ramsden, N.; Bell, K.; Cansfield, A.; Taylor, J.; Sunose, M.; Middlemiss, D.; Neubauer, G. Amino triazoles as PI3K inhibitors. WO2008025821, 2008.
137. Bruce, I.; Dale, J.; Hunt, T. A. Bicyclic heteroaryl compounds and their use as kinase inhibitors. WO2009010530, 2009.
138. Capraro, H-G.; Imbach, P.; Caravatti, G.; Furet, P. Organic compounds. WO2008138834, 2008.
139. Capraro, H-G.; Charavatti, G.; Furet, P.; Imbach, P.; Lan, J.; Pecchi, S.; Schoepfer, J. Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors. WO2008138889, 2008.